GlassScriptPhysician profile
Kingston Okrah
NPI 1528222312
$4,143.08
in general payments reported to CMS, 2019-2025
28 companies · $654 in 2025
The $654 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2021: $66.68 · 2022: $53.64 · 2023: $644 · 2024: $2,584 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Travel and Lodging: $1,457 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.97 |
| Travel and Lodging | $1,457.13 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,929.50 | 2021-2024 | Rotarexs 6 F X 135 Cm, Crosser Iq |
| Novartis Pharmaceuticals Corporation | $191.46 | 2019-2025 | |
| Medtronic, INC. | $191.25 | 2022-2023 | Symplicity G3 |
| Abbott Laboratories | $157.87 | 2025 | Triclip, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Penumbra, INC. | $148.17 | 2024 | Indigo System |
| Boston Scientific Corporation | $143.74 | 2025 | Avvigo Guidance System, Watchman Access System |
| Shockwave Medical, INC | $136.53 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Becton, Dickinson and Company | $136.24 | 2024 | Rotarexs 6 F X 135 Cm |
| Amgen INC. | $121.25 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $109.21 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $104.59 | 2024-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $99.00 | 2023 | |
| Inspire Medical Systems, INC. | $85.64 | 2024 | Inspire |
| Pfizer INC. | $81.97 | 2024 | |
| Edwards Lifesciences Corporation | $76.39 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $65.47 | 2025 | Attruby |
| Daiichi Sankyo INC. | $58.60 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $55.96 | 2023-2024 | Inpefa |
| Cardiovascular Systems INC. | $55.60 | 2019-2023 | Diamondback Peripheral |
| Ethicon US, LLC | $29.41 | 2025 | Stratafix, Vistaseal |
| Terumo Medical Corporation | $27.98 | 2022-2024 | Glidewire |
| Heartflow, INC. | $27.81 | 2025 | |
| Esperion Therapeutics, INC. | $25.42 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $21.28 | 2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.91 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.49 | 2024 | Opsumit |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kingston Okrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.